Safety and Performance of POLYTHESE® Vascular Prosthesis
A Retrospective, Observational, Multicenter, Study to Collect Clinical Safety and Performance Data of POLYTHESE® Vascular Prostheses
POLYTHESE® study is a retrospective, observational, multicentre, case series which examine short and long-term outcomes of using POLYTHESE®. This study will be done on Real World Data to describe the safety and performance of the device.
PMCF Study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Caen, France, 14000
- CHU Caen
-
Nantes, France, 44000
- CHU de Nantes
-
PAris, France, 75014
- Chu La Pitie Salpetriere
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients must meet the following inclusion criteria in order to be eligible for inclusion in the study:
- Patient has a minimum of 1-year post-operative follow-up data available, or complete data to death
Exclusion Criteria:
- none
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Performance: Primary patency rate
Time Frame: 1 year
|
Patency rate
|
1 year
|
|
Safety : Mortality rate
Time Frame: 30 days
|
30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Device Failure
Time Frame: 5 years
|
|
5 years
|
|
Mortality rate
Time Frame: 5 years
|
freedom % from death
|
5 years
|
|
Adverse events
Time Frame: 5 years
|
any documented adverse events, including anticipated and non-anticipated adverse events
|
5 years
|
|
Procedural success rate
Time Frame: 5 years
|
Ability to use with no need for replacement by another device and, Effective vascular flow restoration after procedure and, In case of aneurysm, exclusion of aneurysmal portion after procedure.
|
5 years
|
|
Primary patency rate
Time Frame: 5 years
|
rate patency of the bypass graft without procedure or intervention of the conduit itself (except for occlusion)
|
5 years
|
|
Primary assisted patency rate
Time Frame: 5 years
|
defined as rate patency of the bypass graft with or without procedure or intervention of the conduit itself (except for occlusion) after device implantation
|
5 years
|
|
Secondary patency
Time Frame: 5 years
|
defined as rate patency of the bypass graft with or without procedure or intervention of the conduit itself for occlusion after device implantation
|
5 years
|
|
Limb salvage rate
Time Frame: 5 years
|
defined as freedom % from target limb amputation
|
5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Disease
- Congenital Abnormalities
- Hematologic Diseases
- Hemorrhagic Disorders
- Genetic Diseases, Inborn
- Musculoskeletal Diseases
- Connective Tissue Diseases
- Atherosclerosis
- Hemostatic Disorders
- Skin Diseases, Genetic
- Bone Diseases
- Heart Defects, Congenital
- Cardiovascular Abnormalities
- Musculoskeletal Abnormalities
- Skin Abnormalities
- Abnormalities, Multiple
- Bone Diseases, Developmental
- Limb Deformities, Congenital
- Aneurysm
- Collagen Diseases
- Syndrome
- Peripheral Arterial Disease
- Peripheral Vascular Diseases
- Aneurysm, Dissecting
- Marfan Syndrome
- Arachnodactyly
- Ehlers-Danlos Syndrome
Other Study ID Numbers
Other Study ID Numbers
- 2021-PT-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.